

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new

custom IPC display formats
NEWS 32 JAN 28 MARPAT searching enhanced
NEWS 33 JAN 28 USGENE now provides USPTO sequence data within 3 days
of publication
NEWS 34 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:51:09 ON 19 FEB 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:51:21 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10524162\Struc 1.str



chain nodes :

1 20 21 22 23 34 35

ring nodes :

2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 24 25 26 27 28
29 30 31 32 33

chain bonds :

1-2 1-3 1-4 11-21 18-20 20-22 21-23 22-24 23-25 29-35 33-34

ring bonds :

2-10 2-14 3-15 3-19 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14
15-16 16-17 17-18 18-19 24-26 24-29 25-30 25-33 26-27 27-28 28-29 30-31
31-32 32-33

exact/norm bonds :

20-22 21-23 22-24 23-25 24-26 24-29 25-30 25-33 26-27 27-28 28-29 30-31
31-32 32-33

exact bonds :

1-2 1-3 1-4 11-21 18-20 29-35 33-34

normalized bonds :

2-10 2-14 3-15 3-19 4-5 4-9 5-6 6-7 7-8 8-9 10-11 11-12 12-13 13-14
15-16 16-17 17-18 18-19

Match level :

1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> 11

SAMPLE SEARCH INITIATED 08:51:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6 TO ITERATE

100.0% PROCESSED 6 ITERATIONS 6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 6 TO 266

PROJECTED ANSWERS: 6 TO 266

L2 6 SEA SSS SAM L1

=> 11 full

FULL SEARCH INITIATED 08:51:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 114 TO ITERATE

100.0% PROCESSED 114 ITERATIONS 105 ANSWERS

SEARCH TIME: 00.00.01

L3 105 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 08:52:01 ON 19 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008 VOL 148 ISS 8
FILE LAST UPDATED: 18 Feb 2008 (20080218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 13

L4 10 L3

=> d ibib abs hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:647626 CAPLUS

DOCUMENT NUMBER: 145:224185

TITLE: Cold virus fusion or stopping fusion cold - inhibitors of the human respiratory syncytial virus F protein
AUTHOR(S): Del Vecchio, Alfred M.; Sarisky, Robert T.
CORPORATE SOURCE: Infectious Diseases Research, Centocor, Inc., Radnor, PA, 19087, USA

SOURCE: Recent Patents on Anti-Infective Drug Discovery (2006), 1(2), 247-254
CODEN: RPADCX; ISSN: 1574-891X

PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English


AB A review. Human respiratory syncytial virus (HRSV) is a major respiratory viral pathogen causing moderate to severe upper and lower respiratory tract infections in all ages and across a wide range of patient populations. There are no currently approved vaccines and although a number of candidates are in various stages of development, the challenges are quite substantial. Presently, only a single agent is approved for HRSV prophylaxis, and therapeutic treatment options are severely limited and ineffective, particularly in the infant population. Antibody prophylaxis is restricted to use in populations at high-risk for hospitalization (infants under 35 wk gestational age, infants with chronic lung disease, and infants with congenital heart disease). Aerosol administration of the guanosine analog ribavirin has been approved for the treatment of severe HRSV LRTI in both children and mech. ventilated patients; however, there is still debate over its overall benefit and the risks associated with its use. Current therapy for those hospitalized due to HRSV is supportive. As such, there is great medical need for the development of agents to prevent and treat HRSV infections in all populations. Interestingly, many of the discovered agents against HRSV, both neutralizing antibodies and small mol. inhibitors, target the viral fusion (F) glycoprotein. In particular, three distinct chemical classes as exemplified by JNJ-2408068, VP-14637, and BMS-433771, which appear to block conformational intermediates of the viral fusion protein are reviewed.

IT 235106-62-4, VP-14637

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(cold virus fusion or stopping fusion cold - inhibitors of human
respiratory syncytial virus F protein)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1028388 CAPLUS

DOCUMENT NUMBER: 143:379155

TITLE: Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol

AUTHOR(S): Wyde, Philip R.; Laquerre, Sylvie; Chetty, Srikrishna N.; Gilbert, Brian E.; Nitz, Theodore J.; Pevear, Daniel C.

CORPORATE SOURCE: Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA

SOURCE: Antiviral Research (2005), 68(1), 18-26

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB VP14637, the lead compound in a series of substituted bis-tetrazole-benzhydrylphenols developed by ViroPharma Incorporated, was evaluated for antiviral efficacy against respiratory syncytial virus (RSV) in vitro in cell culture and in vivo in cotton rats. A selective index of > 3000 (≥ 2000 times greater than that observed for ribavirin) was determined in the in vitro studies for this compound against both RSV A and B subtypes. In cotton rats, animals given as little as 126 μg drug/kg by small droplet aerosol in divided doses starting 1 day after exptl. virus infection with either a RSV A or B subtype consistently had significantly lower mean pulmonary RSV titers and reduced histopathol. findings than mock-treated animals or cotton rats given placebo (vehicle-treated animals). No cotton rat treated with aerosols of VP14637 during these studies manifested any evident untoward responses. Thus, VP14637 exhibited good selective antiviral efficacy both in vitro and in vivo.


IT 235106-62-4, VP14637

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiviral efficacy of VP14637 against respiratory syncytial virus in
 vitro and in cotton rats following delivery by small droplet aerosol)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:494325 CAPLUS

DOCUMENT NUMBER: 143:90328

TITLE: Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms

AUTHOR(S): Douglas, Janet L.; Panis, Marites L.; Ho, Edmund; Lin, Kuei-Ying; Krawczyk, Steve H.; Grant, Deborah M.; Cai, Ruby; Swaminathan, Swami; Chen, Xiaowu; Cihlar, Tomas

CORPORATE SOURCE: Gilead, Foster City, CA, 94404, USA

SOURCE: Antimicrobial Agents and Chemotherapy (2005), 49(6), 2460-2466

CODEN: AMACQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Here we present data on the mechanism of action of VP-14637 and JNJ-2408068 (formerly R-170591), two small-mol. inhibitors of respiratory syncytial virus (RSV). Both inhibitors exhibited potent antiviral activity with 50% effective concns. (EC50s) of 1.4 and 2.1 nM, resp. A similar inhibitory effect was observed in a RSV-mediated cell fusion assay (EC50 = 5.4 and 0.9 nM, resp.). Several drug-resistant RSV variants were selected in vitro in the presence of each compound. All selected viruses exhibited significant cross-resistance to both inhibitors and contained various single amino acid substitutions in two distinct regions of the viral F protein, the heptad repeat 2 (HR2; mutations D486N, E487D, and F488Y), and the intervening domain between HR1 and HR2 (mutation K399I and T400A). Studies using [3H]VP-14637 revealed a specific binding of the compound to RSV-infected cells that was efficiently inhibited by JNJ-2408068 (50% inhibitory concentration = 2.9 nM) but not by the HR2-derived peptide T-118.

Further anal. using a transient T7 vaccinia expression system indicated that RSV F protein is sufficient for this interaction. F proteins containing

either the VP-14637 or JNJ-2408068 resistance mutations exhibited greatly reduced binding of [3H]VP-14637. Mol. modeling anal. suggests that both mols. may bind into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains. Altogether, these data indicate that VP-14637 and JNJ-2408068 interfere with RSV fusion through a mechanism involving a similar interaction with the F protein.


IT 235106-62-4, VP-14637

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(small mols. VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms by binding into a small hydrophobic cavity in the inner core of F protein, interacting simultaneously with both the HR1 and HR2 domains)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:142914 CAPLUS

DOCUMENT NUMBER: 140:181453

TITLE: Preparation of 2,2'-(phenylmethylene)bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenol] compounds, pharmaceutical compositions, and methods for treating or preventing pneumovirus infection and associated diseases

INVENTOR(S): Rys, David J.; Nitz, Theodore J.; Gaboury, Janet A.; Burns, Christopher J.; Pevear, Daniel C.; Lessen, Thomas A.; Herbertz, Torsten

PATENT ASSIGNEE(S): Viropharma Incorporated, USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014317	A2	20040219	WO 2003-US25166	20030811

WO 2004014317 A3 20040415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2495245 A1 20040219 CA 2003-2495245 20030811
AU 2003258177 A1 20040225 AU 2003-258177 20030811
EP 1539691 A2 20050615 EP 2003-785209 20030811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2005288345 A1 20051229 US 2005-524313 20050715
PRIORITY APPLN. INFO.: US 2002-402402P P 20020809
WO 2003-US25166 W 20030811
OTHER SOURCE(S): MARPAT 140:181453
GI




AB The title compds. (I; R1 = alkoxy, alkoxyalkyl, halogen, nitro, carboxy, carboxyalkyl, carbalkoxy, carbalkoxyalkyl, carboxamide, carboxamidoalkyl, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfonamide, amidino, cyano, amino, amido, alkylamino, dialkylamino, alkylaminoalkyl, alkoxy monosubstituted with a substituent selected from the group consisting of carboxy, amino, alkylamino and dialkylamino) and pharmaceutically acceptable salts are prepared. Pharmaceutical compns. and methods are also provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections. The compds. I showed IC₅₀ of 0.1 nM to 1 μ M in an cell culture assay for inhibition of Pneumovirus replication using HEp2 cells.

IT 660408-49-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 2,2'-(phenylmethylene)bis[[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)

RN 660408-49-1 CAPLUS

CN Phenol, 2,2'-[(3-propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




IT 660408-51-5P 660408-53-7P 660408-54-8P
 660408-56-0P 660408-58-2P 660408-60-6P
 660408-62-8P 660408-64-0P 660408-66-2P
 660408-68-4P 660408-70-8P 660408-72-0P
 660408-74-2P 660408-76-4P 660408-78-6P
 660408-80-0P 660408-82-2P 660408-84-4P
 660408-86-6P 660408-87-7P 660408-89-9P
 660408-91-3P 660408-93-5P 660408-95-7P
 660408-97-9P 660408-99-1P 660409-01-8P
 660409-03-0P 660409-05-2P 660409-07-4P
 660409-09-6P 660409-11-0P 660409-12-1P
 660409-15-4P 660409-17-6P 660409-19-8P
 660409-21-2P 660409-22-3P 660409-23-4P
 660409-24-5P 660409-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,2'-(phenylmethylene)bis[[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)


RN 660408-51-5 CAPLUS

CN Phenol, 2,2'-[[3-(dimethylamino)phenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-53-7 CAPLUS

CN Phenol, 2,2'-[[3-(1-methylethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-54-8 CAPLUS

CN Phenol, 2,2'-[[3-methylphenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-56-0 CAPLUS


CN Phenol, 2,2'-[[3-methoxyphenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-58-2 CAPLUS
 CN Phenol, 2,2'-[(3-ethoxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 660408-60-6 CAPLUS
 CN Phenol, 2,2'-[(3-chlorophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-62-8 CAPLUS
 CN Phenol, 2,2'-[(3-bromophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-64-0 CAPLUS

CN Phenol, 2,2'-[[3-(2-ethylbutyl)phenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-66-2 CAPLUS

CN Phenol, 2,2'-[[3-(cyclohexylphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-68-4 CAPLUS

CN Phenol, 2,2'-[[3-(butylphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-70-8 CAPLUS

CN Phenol, 2,2'-[(3-fluorophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-72-0 CAPLUS

CN Phenol, 2,2'-[(3-pentylphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-74-2 CAPLUS

CN Phenol, 2,2'-[[3-(1-methylpropyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-76-4 CAPLUS

CN Phenol, 2,2'-[[3-(2-methylpropyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-78-6 CAPLUS

CN Phenol, 2,2'-[[3-(2-methoxyethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-80-0 CAPLUS

CN Phenol, 2,2'-[[3-ethylphenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-82-2 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(1-methylethyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 660408-84-4 CAPLUS

CN Phenol, 2,2'-[[3-(ethylpropylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-86-6 CAPLUS


CN Phenol, 2,2'-[[3-(diethylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660408-87-7 CAPLUS
 CN Phenol, 2,2'-[[3-(butylethylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



RN 660408-89-9 CAPLUS
 CN Phenol, 2,2'-[[3-(methylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 660408-91-3 CAPLUS
 CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-diethyl- (CA INDEX NAME)




RN 660408-93-5 CAPLUS

CN Phenol, 2,2'-[[3-[2-(dimethylamino)ethoxy]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 660408-95-7 CAPLUS

CN Propanamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 660408-97-9 CAPLUS

CN 1-Butanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 660408-99-1 CAPLUS

CN Phenol, 2,2'-[(3-nitrophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-01-8 CAPLUS

CN Phenol, 2,2'-[[3-(methylthio)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-03-0 CAPLUS

CN Phenol, 2,2'-[[3-(methylsulfinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-05-2 CAPLUS

CN Phenol, 2,2'-[[3-(methylsulfonyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-07-4 CAPLUS

CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-dimethyl- (CA INDEX NAME)




RN 660409-09-6 CAPLUS

CN Phenol, 2,2'-[[3-(propylamino)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 660409-11-0 CAPLUS

CN Phenol, 2,2'-[[3-[3-(diethylamino)propoxy]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 660409-12-1 CAPLUS

CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 660409-15-4 CAPLUS


CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 660409-17-6 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 660409-19-8 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-3-methyl-N-propyl- (CA INDEX NAME)




RN 660409-21-2 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-3-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 660409-22-3 CAPLUS
 CN Butanamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N,3-dimethyl- (CA INDEX NAME)



RN 660409-23-4 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-ethyl- (CA INDEX NAME)




RN 660409-24-5 CAPLUS
 CN 1-Propanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)



RN 660409-25-6 CAPLUS

CN Phenol, 2,2'-[[3-[methyl(1-methylethyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




IT 660409-26-7P 660409-27-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prodrug; preparation of 2,2'-(phenylmethylene)bis[[[(methyl-1H-tetrazolyl)imino]methyl]phenol] compds. for treating or preventing pneumovirus infection and associated diseases)


RN 660409-26-7 CAPLUS

CN Phenol, 2,2'-[(3-propylphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]-, dipropanoate (ester) (9CI) (CA INDEX NAME)



RN 660409-27-8 CAPLUS

CN Phenol, 2,2'-[(3-propylphenyl)methylene]bis[4-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]-, diacetate (ester) (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:142913 CAPLUS

DOCUMENT NUMBER: 140:181452

TITLE: Preparation of triaryl bistetrazole derivatives for treating or preventing pneumovirus infection and associated diseases

INVENTOR(S): Nitz, Theodore J.; Gaboury, Janet A.; Burns,
Christopher J.; Laquerre, Sylvie; Pevear, Daniel C.;
Lessen, Thomas A.; Rys, David J.

PATENT ASSIGNEE(S) : Viropharma Incorporated, USA

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004014316	A2	20040219	WO 2003-US25165	20030811
WO 2004014316	A3	20040617		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2495266	A1	20040219	CA 2003-2495266	20030811
AU 2003258176	A1	20040225	AU 2003-258176	20030811
EP 1545513	A2	20050629	EP 2003-785208	20030811
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005288344	A1	20051229	US 2005-524162	20050617
PRIORITY APPLN. INFO.:			US 2002-402450P	P 20020809
			WO 2003-US25165	W 20030811
OTHER SOURCE(S):	MARPAT 140:181452			
GI				



AB The title compound I [R = alkyl, substituted amino, substituted SO₂NH₂, hydroxyalkyl, hydroxyalkoxy, polyhydroxyalkyl, alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, heterocyclyl, etc.] were prepared for treating or preventing pneumovirus infection and associated diseases. Thus, reaction of 2,2'-[[3-(2,2,2-trifluoroethyl)phenyl]methylene]bis(4-formyl)phenol (preparation given) with 1-amino-5-methyltetrazole yielded compound

I (R = CH₂CF₃). The prepared compds. were assayed for the inhibition of the replication of several pneumoviruses with IC₅₀ range from 0.1 nM to 1 μM.

IT 658688-35-8P 658688-36-9P 658688-37-0P


658688-38-1P 658688-39-2P 658688-40-5P
 658688-41-6P 658688-42-7P 658688-43-8P
 658688-44-9P 658688-45-0P 658688-46-1P
 658688-47-2P 658688-48-3P 658688-49-4P
 658688-50-7P 658688-51-8P 658688-52-9P
 658688-53-0P 658688-54-1P 658688-55-2P
 658688-56-3P 658688-57-4P 658688-58-5P
 658688-59-6P 658688-60-9P 658688-61-0P
 658688-62-1P 658688-63-2P 658688-64-3P
 658688-65-4P 658688-66-5P 658688-67-6P
 658688-68-7P 658688-69-8P 658688-70-1P
 658688-71-2P 658688-72-3P 658688-73-4P
 658688-74-5P 658688-75-6P 658688-76-7P
 658688-77-8P 658688-78-9P 658688-79-0P
 658688-80-3P 658688-81-4P 658688-82-5P
 658688-83-6P 658688-84-7P 658688-85-8P
 658688-86-9P 658688-87-0P 658688-88-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of triaryl bistetrazole derivs. for treating or preventing
 pneumovirus infection and associated diseases)


RN 658688-35-8 CAPLUS

CN Phenol, 2,2'-[[3-(2,2,2-trifluoroethyl)phenyl]methylene]bis[4-[[5-methyl-
 1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-36-9 CAPLUS

CN Benzeneethanol, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-, α -acetate (9CI) (CA INDEX NAME)




RN 658688-37-0 CAPLUS

CN Benzeneethanol, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]- (CA INDEX NAME)




RN 658688-38-1 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-39-2 CAPLUS

CN Phenol, 2,2'-[[3-(1-piperidinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-40-5 CAPLUS


CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)



RN 658688-41-6 CAPLUS
 CN Benzenesulfonamide, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 658688-42-7 CAPLUS
 CN Benzenepropanol, 3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 658688-43-8 CAPLUS

CN Morpholine, 4-[[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 658688-44-9 CAPLUS

CN Phenol, 2,2'-[[3-(2-methoxyethoxy)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 658688-45-0 CAPLUS


CN Phenol, 2,2'-[[3-[bis(phenylmethyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)



RN 658688-46-1 CAPLUS


CN Phenol, 2,2'-[[3-[2-(acetyloxy)ethoxy]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)

1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-47-2 CAPLUS

CN Benzenesulfonamide, N-[2-(acetyloxy)ethyl]-3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 658688-48-3 CAPLUS

CN Phenol, 2,2'-[[3-(2-hydroxyethoxy)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 658688-49-4 CAPLUS


CN Acetamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-hydroxy-N-(1-methylethyl)- (CA INDEX NAME)



RN 658688-50-7 CAPLUS
 CN Acetamide, 2-(acetyloxy)-N-[3-bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-N-propyl- (CA INDEX NAME)




RN 658688-51-8 CAPLUS
 CN Phenol, 2,2'-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 658688-52-9 CAPLUS
 CN Phenol, 2,2'-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 658688-51-8
CMF C31 H34 N12 O2




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 658688-53-0 CAPLUS
CN Phenol, 2,2'-[[3-[(diethylamino)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 658688-54-1 CAPLUS
CN Phenol, 2,2'-[[3-[(diethylamino)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 658688-53-0
CMF C30 H33 N11 O2



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 658688-55-2 CAPLUS

CN Phenol, 2,2'-[[3-[(dimethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 658688-56-3 CAPLUS

CN Phenol, 2,2'-[[3-[(dimethylamino)methyl]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 658688-55-2


CMF C28 H29 N11 O2



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 658688-57-4 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinylmethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 658688-58-5 CAPLUS

CN Phenol, 2,2'-[[3-(4-morpholinylmethyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]-, mono(4-methylbenzenesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 658688-57-4


CMF C30 H31 N11 O3



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 658688-59-6 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(4-hydroxybutyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-60-9 CAPLUS


CN Propanamide, 2-(acetyloxy)-N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-methyl- (CA INDEX NAME)




RN 658688-61-0 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-2-methoxy- (CA INDEX NAME)



RN 658688-62-1 CAPLUS
 CN Cyclopropanecarboxamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 658688-63-2 CAPLUS
 CN 1-Butanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-(butylsulfonyl)- (CA INDEX NAME)




RN 658688-64-3 CAPLUS

CN Ethanesulfonamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2,2,2-trifluoro-N-[(2,2,2-trifluoroethyl)sulfonyl]- (CA INDEX NAME)




RN 658688-65-4 CAPLUS


CN Propanamide, N-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]-2-hydroxy-2-methyl- (CA INDEX NAME)




RN 658688-66-5 CAPLUS
 CN 1-Propanesulfonamide, N-[3-bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-(propylsulfonyl)- (CA INDEX NAME)




RN 658688-67-6 CAPLUS
 CN 1-Propanesulfonamide, N-[3-bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-3-chloro-N-[(3-chloropropyl)sulfonyl]- (CA INDEX NAME)




RN 658688-68-7 CAPLUS
 CN Acetamide, 2-(acetyloxy)-N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 658688-69-8 CAPLUS
 CN Methanesulfonamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-N-(methanesulfonyl)- (CA INDEX NAME)




RN 658688-70-1 CAPLUS
 CN Phenol, 2,2'-[[3-(1,1-dioxido-2-isothiazolidinyl)phenyl]methylene]bis[4-
 [[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



RN 658688-71-2 CAPLUS
 CN Acetamide, N-[3-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]-2-hydroxy- (CA INDEX NAME)




RN 658688-72-3 CAPLUS
 CN Phenol, 2,2'-[[3-[ethyl(3-hydroxypropyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-73-4 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(2-hydroxyethyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-74-5 CAPLUS

CN 4-Piperidinol, 1-[3-[bis[2-hydroxy-5-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenyl]- (CA INDEX NAME)




RN 658688-75-6 CAPLUS

CN Phenol, 2,2'-[[3-[(3-hydroxypropyl)methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-76-7 CAPLUS

CN Phenol, 2,2'-[[3-[[4-(acetyloxy)butyl]ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-77-8 CAPLUS

CN Phenol, 2,2'-[[3-[[2-(2-hydroxyethyl)methylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-78-9 CAPLUS

CN Phenol, 2,2'-[[3-[[4-(4-methyl-1H-tetrazol-1-yl)butyl]ethylamino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-79-0 CAPLUS

CN Phenol, 2,2'-[[3-[(2-hydroxyethyl)propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-80-3 CAPLUS

CN Phenol, 2,2'-[[3-[(4-hydroxybutyl)propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-81-4 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(6-hydroxyhexyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-82-5 CAPLUS

CN Phenol, 2,2'-[[3-[ethyl(5-hydroxypentyl)amino]phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (9CI) (CA INDEX NAME)




RN 658688-83-6 CAPLUS

CN Benzenesulfonamide, 4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 658688-84-7 CAPLUS


CN Benzeneethanol, 4-[bis[2-hydroxy-5-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]- (CA INDEX NAME)



RN 658688-85-8 CAPLUS
 CN Morpholine, 4-[[4-[[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 658688-86-9 CAPLUS
 CN Phenol, 2,2'-[[4-(4-morpholinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)




RN 658688-87-0 CAPLUS

CN Benzeneethanol, 4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]phenyl]methyl)-, α -acetate (9CI) (CA INDEX NAME)



RN 658688-88-1 CAPLUS

CN Phenol, 2,2'-[[4-(1-piperidinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl]imino]methyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:742431 CAPLUS

DOCUMENT NUMBER: 140:192261

TITLE: Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro

AUTHOR(S): Wyde, Philip R.; Chetty, Srikrishna N.; Jewell, Alan
M.; Boivin, Guy; Piedra, Pedro A.

CORPORATE SOURCE: Departments of Molecular Virology and Microbiology,
Baylor College of Medicine, Houston, TX, 77030, USA

SOURCE: Antiviral Research (2003), 60(1), 51-59

CODEN: ARSRDR; ISSN: 0166-3542

PUBLISHER: Elsevier Science B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human metapneumovirus (hMPV) is a newly recognized pathogen that like its

better-known relative, human respiratory syncytial virus (hRSV), appears to be ubiquitous and an important cause of respiratory disease in diverse subpopulations. No antivirals or vaccines are currently approved for the treatment or prevention of hMPV infections. However, ribavirin is licensed to treat serious hRSV-induced infections in children and immune globulin designed for i.v. administration (IVIG) and palivizumab (Synagis), a humanized monoclonal antibody preparation, have been utilized as alternatives to vaccines for preventing or reducing the severity of infections caused by this virus. Because both ribavirin and IVIG have broad viral specificities, studies were performed to compare the ability of these two agents to inhibit the replication of hRSV and hMPV in tissue culture-based assays. Two exptl. chemotherapeutic agents (i.e. VP14637 and JNJ2408068) and different antibody preps. were included in this testing for comparison. Ribavirin and the IVIG utilized were found to have equivalent antiviral activity against hMPV and hRSV. In contrast, except for antisera specifically raised against hMPV, all of the other materials tested had marked activity only against hRSV.

IT 235106-62-4, VP14637
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of human metapneumovirus vs. respiratory syncytial virus by ribavirin and immune serum globulin in vitro)
 RN 235106-62-4 CAPLUS
 CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:495542 CAPLUS

DOCUMENT NUMBER: 140:56326

TITLE: Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay

AUTHOR(S): Morton, Craig J.; Cameron, Rachel; Lawrence, Lynne J.; Lin, Bo; Lowe, Melinda; Luttick, Angela; Mason, Anthony; McKimm-Breschkin, Jenny; Parker, Michael W.; Ryan, Jane; Smout, Michael; Sullivan, Jayne; Tucker, Simon P.; Young, Paul R.

CORPORATE SOURCE: Biota Holdings Limited, Victoria, 3004, Australia

SOURCE: Virology (2003), 311(2), 275-288

CODEN: VIRLAX; ISSN: 0042-6822


PUBLISHER: Elsevier Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Respiratory syncytial virus (RSV) is a ubiquitous human pathogen and the leading cause of lower respiratory tract infections in infants. Infection of cells and subsequent formation of syncytia occur through membrane fusion mediated by the RSV fusion protein (RSV-F). A novel in vitro assay of recombinant RSV-F function has been devised and used to characterize a number of escape mutants for three known inhibitors of RSV-F that have been isolated. Homol. modeling of the RSV-F structure has been carried out on the basis of a chimera derived from the crystal structures of the RSV-F core and a fragment from the orthologous fusion protein from Newcastle disease virus (NDV). The structure correlates well with the appearance of RSV-F in electron micrographs, and the residues identified as contributing to specific binding sites for several monoclonal antibodies are arranged in appropriate solvent-accessible clusters. The positions of the characterized resistance mutants in the model structure identify two promising regions for the design of fusion inhibitors.

IT 235106-62-4, VP14637
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (homol. model of F protein of respiratory syncytial virus fusion inhibitor escape mutants and a syncytium formation assay)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:318769 CAPLUS

DOCUMENT NUMBER: 139:173233

TITLE: Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein

AUTHOR(S): Douglas, Janet L.; Panis, Marites L.; Ho, Edmund; Lin, Kuei-Ying; Krawczyk, Steve H.; Grant, Deborah M.; Cai, Ruby; Swaminathan, Swami; Cihlar, Tomas

CORPORATE SOURCE: Gilead, Foster City, CA, 94404, USA

SOURCE: Journal of Virology (2003), 77(9), 5054-5064

CODEN: JOVIAM; ISSN: 0022-538X

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Human respiratory syncytial virus (RSV) is a major cause of respiratory tract infections worldwide. Several novel small-mol. inhibitors of RSV have been identified, but they are still in preclin. or early clin. evaluation. One such inhibitor is a recently discovered triphenol-based mol., VP-14637 (ViroPharma). Initial expts. suggested that VP-14637 acted early and might be an RSV fusion inhibitor. Here we present studies demonstrating that VP-14637 does not block RSV adsorption but inhibits RSV-induced cell-cell fusion and binds specifically to RSV-infected cells with an affinity corresponding to its inhibitory potency. VP-14637 is capable of specifically interacting with the RSV fusion protein expressed by a T7 vaccinia virus system. RSV variants resistant to VP-14637 were selected; they had mutations localized to two distinct regions of the RSV F protein, heptad repeat 2 (HR2) and the intervening domain between heptad repeat 1 (HR1) and HR2. No mutations arose in HR1, suggesting a mechanism other than direct disruption of the heptad repeat interaction. The F proteins containing the resistance mutations exhibited greatly reduced binding of VP-14637. Despite segregating with the membrane fraction following incubation with intact RSV-infected cells, the compound did not bind to membranes isolated from RSV-infected cells. In addition, binding of VP-14637 was substantially compromised at temps. of ≤ 22 . Therefore, we propose that VP-14637 inhibits RSV through a novel mechanism involving an interaction between the compound and a transient conformation of the RSV F protein.

IT 235106-62-4, VP 14637

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of respiratory syncytial virus fusion by the small mol. VP-14637 via specific interactions with F protein)

RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:13479 CAPLUS


DOCUMENT NUMBER: 135:70403

TITLE: VP-14637 ViroPharma

AUTHOR(S): McKimm-Breschkin, Jennifer

CORPORATE SOURCE: Biomolecular Research Institute, Parkville, VIC 3052,

Australia
 SOURCE: Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2000), 1(4), 425-427
 CODEN: COIDAZ
 PUBLISHER: PharmaPress Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review, with 15 refs. VP-14637 is the lead compound in a series of low mol. weight viral replication inhibitors which are under preclin. investigation by ViroPharma for the potential treatment of RSV infection. Phase 1 trials designed to evaluate the safety and pharmacokinetic profile of VP-14637 in healthy human volunteers have begun. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity.
 IT 235106-62-4, VP 14637
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (VP-14637 for treatment of respiratory syncytial virus infection in humans)
 RN 235106-62-4 CAPLUS
 CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:495171 CAPLUS

DOCUMENT NUMBER: 131:144606

TITLE: Preparation of heterocyclyl-substituted methylidynetrisphenol derivatives and related compounds for treating or preventing pneumovirus infection and associated diseases

INVENTOR(S): Nitz, Theodore J.; Pevear, Daniel C.

PATENT ASSIGNEE(S): Viropharma Incorporated, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9938508	A1	19990805	WO 1999-US1985	19990129
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319465	A1	19990805	CA 1999-2319465	19990129
EP 1051169	A1	20001115	EP 1999-905546	19990129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9908522	A	20011002	BR 1999-8522	19990129
JP 2002501894	T	20020122	JP 2000-529241	19990129
NZ 505894	A	20021220	NZ 1999-505894	19990129
AU 759772	B2	20030501	AU 1999-25685	19990129
US 6495580	B1	20021217	US 1999-254690	19991018
MX 2000PA07394	A	20030801	MX 2000-PA7394	20000728
US 2003092685	A1	20030515	US 2002-280528	20021025
IN 2003DE00960	A	20050225	IN 2003-DE960	20030804
PRIORITY APPLN. INFO.:			US 1998-73038P	P 19980129
			US 1998-73078P	P 19980130
			WO 1999-US1985	W 19990129
			IN 1999-DE959	A3 19990710
			US 1999-254690	A3 19991018
OTHER SOURCE(S):	MARPAT 131:144606			
GI				




- AB The title compds. I [Het = 5-7 membered heterocyclic ring; R1 = H, halo, perfluoroalkyl, amino, etc.; R2 = H, OH, thio, alkoxy, etc.; X = N:CH, CH:N, N:N, etc.; Z = H, CHO, OH, X(Het)], useful for treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections, were prepared E.g., 5,5'-bis[1-(((5-amino-1H-tetrazolyl)imino)methyl)]-2,2',4''-methylidynetrisphenol was prepared The antiviral activity of I toward pneumovirus was determined The cytotoxicity of I toward healthy cells was also determined
- IT 235106-62-4P 235106-75-9P 235106-77-1P
235106-79-3P 235106-80-6P 235106-81-7P
235106-83-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclcyl-substituted methylidynetrisphenol derivs. and related compds. for treating or preventing pneumovirus infection)


RN 235106-62-4 CAPLUS

CN Phenol, 2,2'-[(4-hydroxyphenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-75-9 CAPLUS

CN Phenol, 2,2'-[[4-[2-(diethylamino)ethoxy]phenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-77-1 CAPLUS

CN Acetic acid, [4-[bis[2-hydroxy-5-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]phenyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 235106-79-3 CAPLUS

CN Phenol, 2,2'-[[4-(4-pyridinyl)phenyl]methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-80-6 CAPLUS

CN Phenol, 2,2'-[(4-nitrophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)




RN 235106-81-7 CAPLUS

CN Phenol, 2,2'-[(4-aminophenyl)methylene]bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (9CI) (CA INDEX NAME)



RN 235106-83-9 CAPLUS
 CN Phenol, 2,2'-(phenylmethylene)bis[4-[[5-methyl-1H-tetrazol-1-yl)imino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
54.98	233.55

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.00	-8.00

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:52:18 ON 19 FEB 2008